[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1202242A1 - Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab her2 her2 - Google Patents

Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab her2 her2

Info

Publication number
HK1202242A1
HK1202242A1 HK15102729.7A HK15102729A HK1202242A1 HK 1202242 A1 HK1202242 A1 HK 1202242A1 HK 15102729 A HK15102729 A HK 15102729A HK 1202242 A1 HK1202242 A1 HK 1202242A1
Authority
HK
Hong Kong
Prior art keywords
her2
article
manufacture including
dimerization inhibitor
pertuzumab
Prior art date
Application number
HK15102729.7A
Other languages
English (en)
Chinese (zh)
Inventor
Sreedhara Alavattam
Lukas C Amler
Mark C Benyunes
Emma L Clark
Toledo Pelizon Christina H De
Glover Zephania W Kwong
Lada Mitchell
Jayantha Ratnayake
Graham A Ross
Ru-Amir Walker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47073543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1202242A1 publication Critical patent/HK1202242A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15102729.7A 2011-10-14 2015-03-17 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab her2 her2 HK1202242A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161547535P 2011-10-14 2011-10-14
US201161567015P 2011-12-05 2011-12-05
US201261657669P 2012-06-08 2012-06-08
US201261682037P 2012-08-10 2012-08-10
US201261694584P 2012-08-29 2012-08-29
PCT/US2012/059683 WO2013055874A2 (fr) 2011-10-14 2012-10-11 Utilisations d'un article de manufacture comprenant du pertuzumab inhibiteur de dimérisation de her2 et article manufacture comprenant du pertuzumab inhibiteur de dimérisation de her2

Publications (1)

Publication Number Publication Date
HK1202242A1 true HK1202242A1 (en) 2015-09-25

Family

ID=47073543

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102729.7A HK1202242A1 (en) 2011-10-14 2015-03-17 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab her2 her2

Country Status (29)

Country Link
US (9) US20130095172A1 (fr)
EP (6) EP4234034A3 (fr)
JP (8) JP2014530235A (fr)
KR (5) KR102099991B1 (fr)
CN (8) CN116236569A (fr)
AU (4) AU2012322797B2 (fr)
BR (1) BR112014007521A8 (fr)
CL (1) CL2014000889A1 (fr)
DK (1) DK2766040T3 (fr)
EA (1) EA034390B1 (fr)
ES (1) ES2736005T3 (fr)
HK (1) HK1202242A1 (fr)
HR (1) HRP20191247T1 (fr)
HU (1) HUE044352T2 (fr)
IL (4) IL309917A (fr)
IN (1) IN2014CN02703A (fr)
LT (1) LT2766040T (fr)
MX (2) MX2014004021A (fr)
MY (2) MY194408A (fr)
PE (1) PE20142363A1 (fr)
PH (1) PH12019500519A1 (fr)
PL (1) PL2766040T3 (fr)
PT (2) PT2766040T (fr)
RS (1) RS58944B1 (fr)
SG (3) SG10202110077QA (fr)
SI (1) SI2766040T1 (fr)
UA (2) UA123092C2 (fr)
WO (1) WO2013055874A2 (fr)
ZA (1) ZA201401259B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN106967062A (zh) 2008-11-03 2017-07-21 辛塔佳股份有限公司 新型cc‑1065类似物及其缀合物
ES2660428T3 (es) 2010-04-21 2018-03-22 Syntarga B.V. Conjugados de análogos de CC-1065 y conectores bifuncionales
UA123092C2 (uk) 2011-10-14 2021-02-17 Дженентек, Інк. Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
SG11201508536PA (en) 2013-04-16 2015-11-27 Genentech Inc Pertuzumab variants and evaluation thereof
SG11201509508YA (en) * 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN104726462A (zh) * 2013-12-20 2015-06-24 北京天广实生物技术股份有限公司 抗her2人源化抗体mil41、其制备方法及用途
RU2689779C2 (ru) * 2014-01-10 2019-05-29 Синтон Байофармасьютикалс Б. В. Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
PT3092010T (pt) 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
PT2948183T (pt) * 2014-01-10 2016-07-13 Univ Yale Conjugados anticorpo-fármaco de duocarmicina para utilização no tratamento de cancro do endométrio
WO2016094341A1 (fr) * 2014-12-08 2016-06-16 Synta Pharmaceuticals Corp. Thérapie à triple combinaison, comportant du ganetespib, un taxane et un anticorps, pour utilisation dans le traitement de cancer du sein her2 positif
EP3304072A4 (fr) * 2015-05-29 2018-12-05 Expression Pathology, Inc. Quantification de la protéine her2 pour une thérapie anticancéreuse optimale
MX2017016353A (es) 2015-06-17 2018-05-02 Genentech Inc Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
CA3040913A1 (fr) * 2016-11-04 2018-05-11 Genentech, Inc. Traitement du cancer du sein her2-positif
CA3046092A1 (fr) * 2016-12-28 2018-07-05 Genentech, Inc. Traitement du cancer exprimant her2 avance
CN111714630B (zh) * 2017-01-17 2021-11-09 基因泰克公司 皮下her2抗体配制剂
IL301279B2 (en) 2017-03-02 2024-06-01 Hoffmann La Roche Adjuvant treatment for HER2-positive breast cancer
KR102267593B1 (ko) * 2018-10-19 2021-06-21 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
CN114144169A (zh) * 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
JP2022538865A (ja) 2019-06-28 2022-09-06 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム リポソーム化アナマイシン前駆体凍結乾燥物の調製
BR112021026480A2 (pt) * 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
US20230175069A1 (en) * 2020-04-29 2023-06-08 University Of Pittsburgh-Of The Commonweal Th System Of Higher Education Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
KR20240119103A (ko) * 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
EP0494135B1 (fr) 1989-09-29 1996-04-10 Oncogene Science, Inc. Protéine humaine "neu" p100 et son utilisation pour la détection de cellules prénéoplasiques ou néoplasiques chez l'homme
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CN1151842C (zh) 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
EP0950067B1 (fr) 1996-11-27 2007-08-29 Genentech, Inc. Purification par affinite de polypeptide sur une matrice de proteines a
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1064027B1 (fr) 1998-03-27 2008-06-18 Genentech, Inc. Synergie des anticorps anti-her-2 et des ligands pour l'apo-2
DE69907439T3 (de) 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1187632B1 (fr) 1999-05-14 2008-12-03 Genentech, Inc. TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
MXPA01013458A (es) 1999-06-25 2002-07-30 Genentech Inc Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2.
CA2383493C (fr) 1999-06-25 2010-08-10 Genentech, Inc. Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
WO2001015730A1 (fr) 1999-08-27 2001-03-08 Genentech, Inc. DOSAGES POUR TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
KR20080038458A (ko) 2000-05-19 2008-05-06 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
EP1585966B8 (fr) 2002-07-15 2012-03-07 F. Hoffmann-La Roche AG Traitment de cancer par l'anticorps rhuMAb 2C4
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
WO2004030621A2 (fr) * 2002-09-30 2004-04-15 The Trustees Of Boston University Methode de traitement du cancer faisant appel a l'adenosine et a ses analogues
AU2003295798B2 (en) 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
CA2563341C (fr) 2004-04-08 2014-10-21 David B. Agus Antagonistes d'erbb pour le traitement de la douleur
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20050280299A1 (en) 2004-06-18 2005-12-22 Alfmeier Corporation Mounting adaptor for seat assembly, and seat assembly having mounting adaptor
CN101023100B (zh) 2004-07-22 2012-08-29 健泰科生物技术公司 Her2抗体组合物
EP1778728A2 (fr) 2004-08-19 2007-05-02 Genentech, Inc. Variants de polypeptides dotes d'une fonction effectrice modifiee
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1819735A1 (fr) * 2004-11-04 2007-08-22 Pfizer Products Inc. Anticorps ctla-4 et inhibiteur de l'aromatase ou traitement combine du cancer du sein
BRPI0518086A (pt) 2004-12-07 2008-10-28 Genentech Inc métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
ZA200706017B (en) 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
NZ560879A (en) * 2005-02-18 2010-04-30 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
WO2006096861A2 (fr) 2005-03-08 2006-09-14 Genentech, Inc. Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US20080038271A1 (en) * 2006-06-05 2008-02-14 Amler Lukas C Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
CN101466468B (zh) 2006-06-14 2012-05-23 株式会社科特拉 排气净化用催化剂
SG174090A1 (en) 2006-08-21 2011-09-29 Hoffmann La Roche Tumor therapy with an anti-vegf antibody
WO2008031531A1 (fr) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Thérapie antitumorale avec une combinaison d'anticorps anti-her2
PE20090681A1 (es) * 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
BRPI0812777A2 (pt) 2007-06-06 2014-12-02 Hoffmann La Roche Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
EP2205242B1 (fr) 2007-09-12 2015-04-15 Genentech, Inc. Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
SI2565206T1 (sl) 2007-10-30 2016-07-29 Genentech, Inc. Čiščenje protitelesa s kationsko izmenjevalno kromatografijo
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090203015A1 (en) * 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
TW200942552A (en) 2008-03-06 2009-10-16 Genentech Inc Combination therapy with c-Met and HER antagonists
AR070865A1 (es) 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2535404T5 (es) * 2008-11-22 2018-11-19 F. Hoffmann-La Roche Ag Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
UA123092C2 (uk) 2011-10-14 2021-02-17 Дженентек, Інк. Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта

Also Published As

Publication number Publication date
EP2766040B1 (fr) 2019-05-15
JP2023109780A (ja) 2023-08-08
JP2020090507A (ja) 2020-06-11
ZA201401259B (en) 2019-01-30
IL301603A (en) 2023-05-01
US20200206348A1 (en) 2020-07-02
KR102679155B1 (ko) 2024-06-28
CN116271013A (zh) 2023-06-23
EP4234034A3 (fr) 2023-09-20
JP7352760B2 (ja) 2023-09-28
EP4241849A3 (fr) 2023-09-20
JP2017222663A (ja) 2017-12-21
EP3598981A3 (fr) 2020-06-10
IL231350A0 (en) 2014-04-30
PT4241849T (pt) 2024-10-30
US20230277664A1 (en) 2023-09-07
IL231350B2 (en) 2023-08-01
KR20230073340A (ko) 2023-05-25
KR102099991B1 (ko) 2020-04-14
US20130095172A1 (en) 2013-04-18
CN114984205A (zh) 2022-09-02
JP2024009803A (ja) 2024-01-23
ES2736005T3 (es) 2019-12-23
JP6646785B1 (ja) 2020-02-14
PT2766040T (pt) 2019-07-11
EP4241849B1 (fr) 2024-09-18
US20220362379A1 (en) 2022-11-17
KR20170023195A (ko) 2017-03-02
CN116808199A (zh) 2023-09-29
NZ621367A (en) 2016-04-29
AU2016204962B2 (en) 2018-03-08
EP4403228A3 (fr) 2024-10-23
EP4403228A2 (fr) 2024-07-24
LT2766040T (lt) 2019-08-12
UA123092C2 (uk) 2021-02-17
EA034390B1 (ru) 2020-02-03
CL2014000889A1 (es) 2014-07-25
SI2766040T1 (sl) 2019-08-30
KR20140075725A (ko) 2014-06-19
EP3598981A2 (fr) 2020-01-29
JP2020033353A (ja) 2020-03-05
AU2018203970B2 (en) 2019-11-21
JP2023109779A (ja) 2023-08-08
IL309917A (en) 2024-03-01
US20160175438A1 (en) 2016-06-23
US20190117769A1 (en) 2019-04-25
CN116271011B (zh) 2023-10-27
SG10201606756PA (en) 2016-10-28
WO2013055874A3 (fr) 2013-06-20
AU2012322797A8 (en) 2014-06-26
MX2019009153A (es) 2019-10-14
IN2014CN02703A (fr) 2015-07-03
BR112014007521A8 (pt) 2018-04-10
CN109908341B (zh) 2023-06-27
PL2766040T3 (pl) 2019-11-29
EP4234033A3 (fr) 2023-09-20
EP4234033A2 (fr) 2023-08-30
KR102502545B1 (ko) 2023-02-21
AU2012322797B2 (en) 2016-04-21
UA116095C2 (uk) 2018-02-12
US20210015919A1 (en) 2021-01-21
AU2018203970A1 (en) 2018-06-21
SG10202110077QA (en) 2021-10-28
CN104334189A (zh) 2015-02-04
EP2766040A2 (fr) 2014-08-20
IL286921A (en) 2021-10-31
WO2013055874A2 (fr) 2013-04-18
AU2012322797A1 (en) 2014-03-20
RS58944B1 (sr) 2019-08-30
AU2019261666B2 (en) 2021-08-05
EP4234034A2 (fr) 2023-08-30
CN117018187A (zh) 2023-11-10
MY172326A (en) 2019-11-21
CN116271011A (zh) 2023-06-23
PH12019500519A1 (en) 2021-06-14
JP7303957B1 (ja) 2023-07-05
DK2766040T3 (da) 2019-07-22
KR20230028585A (ko) 2023-02-28
PE20142363A1 (es) 2015-01-30
BR112014007521A2 (pt) 2017-12-12
NZ750877A (en) 2020-09-25
AU2016204962A1 (en) 2016-08-04
US20230277663A1 (en) 2023-09-07
HRP20191247T1 (hr) 2019-10-18
EA201490779A1 (ru) 2015-11-30
IL231350B1 (en) 2023-04-01
MX2014004021A (es) 2014-04-30
EP4241849A2 (fr) 2023-09-13
CN109908341A (zh) 2019-06-21
CN116236569A (zh) 2023-06-09
AU2019261666A1 (en) 2019-11-28
MY194408A (en) 2022-11-30
SG11201401432XA (en) 2014-05-29
US20200376120A1 (en) 2020-12-03
JP2014530235A (ja) 2014-11-17
KR20240109285A (ko) 2024-07-10
HUE044352T2 (hu) 2019-10-28
JP2022062010A (ja) 2022-04-19

Similar Documents

Publication Publication Date Title
HK1202242A1 (en) Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab her2 her2
SG11201400630WA (en) Abrasive article and method of forming
AU347566S (en) Article of jewellery
EP2726247A4 (fr) Article abrasif et son procédé de fabrication
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
EP2866975A4 (fr) Article abrasif et procédé de formation
ZA201305403B (en) Abrasive article and method of forming
EP2772483A4 (fr) Compose 4-aminocarbazole et son utilisation
EP2665724A4 (fr) Inhibiteurs bicycliques de l'alk
EP2866972A4 (fr) Article abrasif et son procédé de formation
IL232186A0 (en) A method for preparing anti-hemorrhagic products
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
GB201107692D0 (en) Sterilisation of packed articles
IL213865A0 (en) Antiballistic article and method of producing same
IL233381A0 (en) Grinding tools and a method for their production
EP2747975A4 (fr) Article manufacturé et son procédé de préparation
EP2724696A4 (fr) Article à porter et procédé pour produire celui-ci
HK1210598A1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation --
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
GB201114576D0 (en) Articles of kitchenware
GB2492864B (en) Article of footwear
EP2798034A4 (fr) Article abrasif aggloméré et procédé de formage
EP2665727A4 (fr) Inhibiteurs de kinases à base de carboxamides bicycliques
EP2900423A4 (fr) Article abrasif et procédé de formation
ZA201701050B (en) Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab